The present inventors successfully produced therapeutic agents for non-small cell lung cancer except adenocarcinoma, comprising as active ingredient an anti-Epiregulin antibody that shows cross-species reactivity between the human animal and cynomolgus which is a non-human animal, an anti-Epiregulin antibody with suppressed chemical degradation, an anti-Epiregulin antibody with reduced isoelectric point, an anti-Epiregulin antibody with increased midpoint temperature of thermal denaturation, or an anti-Epiregulin antibody with reduced amount of aggregates, generated by appropriately substituting amino acid residues in the variable-region sequences of a humanized EP27 antibody that inhibits cancer cell proliferation by exerting a cytotoxicity and a neutralizing activity against human Epiregulin-expressing cancer cells.
本发明者成功地生产了治疗非腺癌非小细胞肺癌的治疗剂,其包含一种抗Epiregulin
抗体作为活性成分,该
抗体在人类动物和恒河猴等非人类动物之间显示跨物种反应性,或者是一种具有抑制
化学降解的抗Epiregulin
抗体,或者是一种具有降低等电点的抗Epiregulin
抗体,或者是一种具有提高热变性中点温度的抗Epiregulin
抗体,或者是一种具有减少聚集物量的抗Epiregulin
抗体,通过在人源化的EP27
抗体的可变区序列中适当替换
氨基酸残基产生,该
抗体通过对表达人类Epiregulin的癌细胞施加细胞毒性和中和活性来抑制癌细胞增殖。